S&P 500   3,662.45 (+1.13%)
DOW   29,823.92 (+0.63%)
QQQ   304.01 (+1.47%)
AAPL   122.85 (+3.19%)
MSFT   215.90 (+0.85%)
FB   286.70 (+3.51%)
GOOGL   1,795.70 (+2.35%)
AMZN   3,222.72 (+1.73%)
TSLA   583.30 (+2.77%)
NVDA   535.00 (-0.20%)
BABA   264.19 (+0.32%)
CGC   26.70 (-7.29%)
GE   10.17 (-0.10%)
MU   67.09 (+4.68%)
AMD   92.49 (-0.18%)
T   28.82 (+0.24%)
NIO   45.94 (-9.08%)
F   9.24 (+1.76%)
ACB   10.12 (-13.36%)
NFLX   504.99 (+2.91%)
BA   213.38 (+1.27%)
GILD   61.12 (+0.74%)
DIS   149.09 (+0.73%)
S&P 500   3,662.45 (+1.13%)
DOW   29,823.92 (+0.63%)
QQQ   304.01 (+1.47%)
AAPL   122.85 (+3.19%)
MSFT   215.90 (+0.85%)
FB   286.70 (+3.51%)
GOOGL   1,795.70 (+2.35%)
AMZN   3,222.72 (+1.73%)
TSLA   583.30 (+2.77%)
NVDA   535.00 (-0.20%)
BABA   264.19 (+0.32%)
CGC   26.70 (-7.29%)
GE   10.17 (-0.10%)
MU   67.09 (+4.68%)
AMD   92.49 (-0.18%)
T   28.82 (+0.24%)
NIO   45.94 (-9.08%)
F   9.24 (+1.76%)
ACB   10.12 (-13.36%)
NFLX   504.99 (+2.91%)
BA   213.38 (+1.27%)
GILD   61.12 (+0.74%)
DIS   149.09 (+0.73%)
S&P 500   3,662.45 (+1.13%)
DOW   29,823.92 (+0.63%)
QQQ   304.01 (+1.47%)
AAPL   122.85 (+3.19%)
MSFT   215.90 (+0.85%)
FB   286.70 (+3.51%)
GOOGL   1,795.70 (+2.35%)
AMZN   3,222.72 (+1.73%)
TSLA   583.30 (+2.77%)
NVDA   535.00 (-0.20%)
BABA   264.19 (+0.32%)
CGC   26.70 (-7.29%)
GE   10.17 (-0.10%)
MU   67.09 (+4.68%)
AMD   92.49 (-0.18%)
T   28.82 (+0.24%)
NIO   45.94 (-9.08%)
F   9.24 (+1.76%)
ACB   10.12 (-13.36%)
NFLX   504.99 (+2.91%)
BA   213.38 (+1.27%)
GILD   61.12 (+0.74%)
DIS   149.09 (+0.73%)
S&P 500   3,662.45 (+1.13%)
DOW   29,823.92 (+0.63%)
QQQ   304.01 (+1.47%)
AAPL   122.85 (+3.19%)
MSFT   215.90 (+0.85%)
FB   286.70 (+3.51%)
GOOGL   1,795.70 (+2.35%)
AMZN   3,222.72 (+1.73%)
TSLA   583.30 (+2.77%)
NVDA   535.00 (-0.20%)
BABA   264.19 (+0.32%)
CGC   26.70 (-7.29%)
GE   10.17 (-0.10%)
MU   67.09 (+4.68%)
AMD   92.49 (-0.18%)
T   28.82 (+0.24%)
NIO   45.94 (-9.08%)
F   9.24 (+1.76%)
ACB   10.12 (-13.36%)
NFLX   504.99 (+2.91%)
BA   213.38 (+1.27%)
GILD   61.12 (+0.74%)
DIS   149.09 (+0.73%)
Log in
NASDAQ:TCDA

Tricida Stock Forecast, Price & News

$7.38
+0.07 (+0.96 %)
(As of 12/1/2020 03:59 PM ET)
Add
Compare
Today's Range
$7.21
Now: $7.38
$7.64
50-Day Range
$4.37
MA: $7.51
$9.37
52-Week Range
$3.74
Now: $7.38
$44.30
Volume22,814 shs
Average Volume691,932 shs
Market Capitalization$370.37 million
P/E RatioN/A
Dividend YieldN/A
Beta1.07
Tricida, Inc., a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). The company has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. Tricida, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
Tricida logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.80 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TCDA
CUSIPN/A
CIKN/A
Phone415-429-7800
Employees157

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.32 per share

Profitability

Net Income$-176,810,000.00

Miscellaneous

Market Cap$370.37 million
Next Earnings Date2/25/2021 (Estimated)
OptionableNot Optionable
$7.38
+0.07 (+0.96 %)
(As of 12/1/2020 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TCDA News and Ratings via Email

Sign-up to receive the latest news and ratings for TCDA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Tricida (NASDAQ:TCDA) Frequently Asked Questions

How has Tricida's stock price been impacted by Coronavirus (COVID-19)?

Tricida's stock was trading at $28.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TCDA stock has decreased by 74.0% and is now trading at $7.30.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Tricida?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Tricida
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Tricida?

Wall Street analysts have given Tricida a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Tricida wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Tricida's next earnings date?

Tricida is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Tricida
.

How were Tricida's earnings last quarter?

Tricida, Inc. (NASDAQ:TCDA) issued its quarterly earnings data on Monday, November, 9th. The company reported ($1.55) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.22) by $0.33.
View Tricida's earnings history
.

What price target have analysts set for TCDA?

4 brokers have issued 1 year price targets for Tricida's shares. Their forecasts range from $8.00 to $40.00. On average, they anticipate Tricida's stock price to reach $19.50 in the next year. This suggests a possible upside of 167.1% from the stock's current price.
View analysts' price targets for Tricida
.

Are investors shorting Tricida?

Tricida saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 4,380,000 shares, an increase of 25.9% from the October 31st total of 3,480,000 shares. Based on an average daily volume of 1,180,000 shares, the short-interest ratio is presently 3.7 days. Approximately 11.2% of the shares of the stock are sold short.
View Tricida's Short Interest
.

Who are some of Tricida's key competitors?

What other stocks do shareholders of Tricida own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Atara Biotherapeutics (ATRA), bluebird bio (BLUE), Moderna (MRNA) and AT&T (T).

Who are Tricida's key executives?

Tricida's management team includes the following people:
  • Dr. Gerrit Klaerner, Founder, Pres, CEO & Exec. Director (Age 49, Pay $973.69k)
  • Mr. Geoffrey M. Parker, CFO & Exec. VP (Age 55, Pay $621.02k)
  • Mr. Edward J. Hejlek Esq., J.D., Exec. VP of Intellectual Property (Age 64, Pay $549.83k)
  • Dr. Dawn Parsell Ph.D., Exec. VP of Clinical Devel. (Age 57, Pay $578.62k)
  • Mr. Marc Cobo, Sr. VP of Fin. & Chief Accounting Officer (Age 40)
  • Dr. Wilhelm Stahl, Exec. VP & CTO (Age 60)
  • Jackie Cossmon, VP of Investor Relations & Communications
  • Mr. Robert L. McKague J.D., Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer

When did Tricida IPO?

(TCDA) raised $175 million in an IPO on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen served as the underwriters for the IPO.

What is Tricida's stock symbol?

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Who are Tricida's major shareholders?

Tricida's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (4.90%), JPMorgan Chase & Co. (2.74%), Point72 Asset Management L.P. (2.41%), Federated Hermes Inc. (2.19%), State Street Corp (1.08%) and Massachusetts Financial Services Co. MA (0.74%). Company insiders that own Tricida stock include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Klaus R Dr Veitinger, Orbimed Advisors Llc, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP and Wilhelm Stahl.
View institutional ownership trends for Tricida
.

Which institutional investors are selling Tricida stock?

TCDA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., State Street Corp, TD Asset Management Inc., SG Americas Securities LLC, Aigen Investment Management LP, Massachusetts Financial Services Co. MA, and California Public Employees Retirement System. Company insiders that have sold Tricida company stock in the last year include Dawn Parsell Otto, Edward J Hejlek, Gerrit Klaerner, Sandra I Coufal, and Wilhelm Stahl.
View insider buying and selling activity for Tricida
.

Which institutional investors are buying Tricida stock?

TCDA stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Point72 Asset Management L.P., Voloridge Investment Management LLC, Aperio Group LLC, Engineers Gate Manager LP, Squarepoint Ops LLC, Berman Capital Advisors LLC, and ExodusPoint Capital Management LP. Company insiders that have bought Tricida stock in the last two years include Geoffrey M Parker, and Orbimed Advisors Llc.
View insider buying and selling activity for Tricida
.

How do I buy shares of Tricida?

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tricida's stock price today?

One share of TCDA stock can currently be purchased for approximately $7.30.

How big of a company is Tricida?

Tricida has a market capitalization of $366.35 million. The company earns $-176,810,000.00 in net income (profit) each year or ($3.72) on an earnings per share basis. Tricida employs 157 workers across the globe.

What is Tricida's official website?

The official website for Tricida is www.tricida.com.

How can I contact Tricida?

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]

This page was last updated on 12/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.